VolitionRx Ltd. has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc., to promote Volition's Nu.Q Discover service to drug developers and scientists. The program offers a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies, representing a significant expansion of customer access to these proprietary tools.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, described the partnership as a significant milestone for the Nu.Q Discover program. This collaboration will greatly expand customer access to our proprietary Nu.Q Discover assays, which have an estimated total addressable market of $200 million annually, Kway stated. The company looks forward to working with the Hologic team to strengthen its position in the pharmaco-epigenetics market and grow revenues through this expanded distribution channel.
Raphael Werding, Head of Life Sciences at Hologic, expressed enthusiasm for adding Nu.Q Discover to the company's service offering. At Hologic, we have extensive experience not only in oncology but also in other disease areas such as cardiovascular, neurodegenerative, immunology and others; disease areas where we believe nucleosome quantification can provide additional valuable biological insights to our biotech, pharma and academic clients, Werding commented. The partnership leverages Hologic's established customer relationships and expertise across multiple therapeutic areas.
Under the agreement terms, Hologic will co-market Nu.Q Discover with its customer base for an initial one-year term. The arrangement includes potential for expansion into an exclusive provider relationship subject to further terms and performance metrics. This strategic partnership represents Volition's continued focus on advancing epigenetics science through collaborations with established industry leaders. For additional information about Volition's technology and services, visit https://www.Volition.com.
The collaboration between these two companies signals growing recognition of epigenetic profiling's importance in drug development and disease research. By combining Volition's specialized epigenetic assays with Hologic's broad industry reach and expertise, the partnership aims to accelerate adoption of nucleosome quantification technologies across multiple disease areas. This expanded access to epigenetic profiling tools could potentially accelerate drug discovery timelines and improve understanding of disease mechanisms for pharmaceutical companies and academic researchers alike.
